Works matching 5Q deletion syndrome

Results: 126
    1
    2

    Evolution of severe (transfusion‐dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage‐associated failure of the eythropoietic niche.

    Published in:
    British Journal of Haematology, 2022, v. 198, n. 1, p. 114, doi. 10.1111/bjh.18163
    By:
    • Buesche, Guntram;
    • Teoman, Huesniye;
    • Schneider, Rebekka K.;
    • Ribezzo, Flavia;
    • Ebert, Benjamin L.;
    • Giagounidis, Aristoteles;
    • Göhring, Gudrun;
    • Schlegelberger, Brigitte;
    • Bock, Oliver;
    • Ganser, Arnold;
    • Aul, Carlo;
    • Germing, Ulrich;
    • Kreipe, Hans
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10
    11

    Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q).

    Published in:
    2021
    By:
    • Hecht, Anna;
    • Meyer, Julia A.;
    • Jann, Johann-Christoph;
    • Sockel, Katja;
    • Giagounidis, Aristoteles;
    • Götze, Katharina S.;
    • Letsch, Anne;
    • Haase, Detlef;
    • Schlenk, Richard F.;
    • Haferlach, Torsten;
    • Schafhausen, Philippe;
    • Bug, Gesine;
    • Lübbert, Michael;
    • Thol, Felicitas;
    • Büsche, Guntram;
    • Schuler, Esther;
    • Nowak, Verena;
    • Obländer, Julia;
    • Fey, Stephanie;
    • Müller, Nadine
    Publication type:
    journal article
    12
    13
    14

    Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.

    Published in:
    European Journal of Haematology, 2010, v. 85, n. 3, p. 231, doi. 10.1111/j.1600-0609.2010.01473.x
    By:
    • Oliva, Esther N.;
    • Cuzzola, Maria;
    • Nobile, Francesco;
    • Ronco, Francesca;
    • D'Errigo, Maria Grazia;
    • Lagan, Carmelo;
    • Morabito, Fortunato;
    • Galimberti, Sara;
    • Cortelezzi, Agostino;
    • Aloe Spiriti, Maria A.;
    • Specchia, Giorgina;
    • Poloni, Antonella;
    • Breccia, Massimo;
    • Ghio, Riccardo;
    • Finelli, Carlo;
    • Iacopino, Pasquale;
    • Alimena, Giuliana;
    • Latagliata, Roberto
    Publication type:
    Article
    15
    16

    Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.

    Published in:
    British Journal of Haematology, 2014, v. 166, n. 2, p. 189, doi. 10.1111/bjh.12876
    By:
    • Sánchez‐García, Joaquín;
    • del Cañizo, Consuelo;
    • Lorenzo, Ignacio;
    • Nomdedeu, Benet;
    • Luño, Elisa;
    • Paz, Raquel;
    • Xicoy, Blanca;
    • Valcárcel, David;
    • Brunet, Salut;
    • Marco‐Betes, Victor;
    • García‐Pintos, Marta;
    • Osorio, Santiago;
    • Tormo, Mar;
    • Bailén, Alicia;
    • Cerveró, Carlos;
    • Ramos, Fernando;
    • Diez‐Campelo, María;
    • Such, Esperanza;
    • Arrizabalaga, Beatriz;
    • Azaceta, Gemma
    Publication type:
    Article
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27

    Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.

    Published in:
    Blood Cancer Journal, 2022, v. 12, n. 9, p. 1, doi. 10.1038/s41408-022-00724-3
    By:
    • Gurnari, Carmelo;
    • Piciocchi, Alfonso;
    • Soddu, Stefano;
    • Bonanni, Fabrizio;
    • Scalzulli, Emilia;
    • Niscola, Pasquale;
    • Di Veroli, Ambra;
    • Piccioni, Anna Lina;
    • Piedimonte, Monica;
    • Maiorana, Gianluca;
    • Salutari, Prassede;
    • Cicconi, Laura;
    • Santopietro, Michelina;
    • Gumenyuk, Svitlana;
    • Sarlo, Chiara;
    • Fenu, Susanna;
    • Tafuri, Agostino;
    • Latagliata, Roberto;
    • Fianchi, Luana;
    • Criscuolo, Marianna
    Publication type:
    Article
    28

    Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.

    Published in:
    Mycoses, 2015, v. 58, n. 9, p. 565, doi. 10.1111/myc.12357
    By:
    • Cho, Sung‐Yeon;
    • Lee, Dong‐Gun;
    • Choi, Su‐Mi;
    • Choi, Jae‐Ki;
    • Lee, Hyo‐Jin;
    • Kim, Si‐Hyun;
    • Park, Sun Hee;
    • Choi, Jung‐Hyun;
    • Yoo, Jin‐Hong;
    • Kim, Yoo‐Jin;
    • Kim, Hee‐Je;
    • Min, Woo‐Sung
    Publication type:
    Article
    29
    30
    31
    32
    33

    Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia.

    Published in:
    Leukemia & Lymphoma, 2018, v. 59, n. 5, p. 1095, doi. 10.1080/10428194.2017.1366998
    By:
    • On behalf of Grupo Andaluz SMD;
    • Sanchez-Garcia, Joaquin;
    • Casaño, Francisco Javier;
    • Serrano, Josefina;
    • Falantes, Jose;
    • Solé Rodriguez, María;
    • Calderon, Cristina;
    • Medina Perez, Angeles;
    • Hernandez-Mohedo, Francisca;
    • Hermosin, Lourdes;
    • Torres-Sabariego, Angeles;
    • Labrador, Maria;
    • Vahí, Maria;
    • Bailen, Alicia;
    • Hernandez-Sanchez, Jesus M.;
    • Lumbreras, Eva;
    • Hernández-Rivas, Jesus Maria
    Publication type:
    Article
    34

    Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q.

    Published in:
    American Journal of Hematology, 2021, v. 96, n. 6, p. E207, doi. 10.1002/ajh.26162
    By:
    • Panagiota, Victoria;
    • Meggendorfer, Manja;
    • Kubasch, Anne Sophie;
    • Gabdoulline, Razif;
    • Krönke, Jan;
    • Mies, Anna;
    • Shahswar, Rabia;
    • Kandziora, Christian;
    • Klement, Piroska;
    • Schiller, Johannes;
    • Göhring, Gudrun;
    • Haferlach, Claudia;
    • Ganster, Christina;
    • Shirneshan, Katayoon;
    • Gutermuth, Annika;
    • Thiede, Christian;
    • Germing, Ulrich;
    • Schroeder, Thomas;
    • Kobbe, Guido;
    • Klesse, Sabrina
    Publication type:
    Article
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46

    High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.

    Published in:
    European Journal of Haematology, 2015, v. 95, n. 1, p. 27, doi. 10.1111/ejh.12457
    By:
    • Jonasova, Anna;
    • Bokorova, Radka;
    • Polak, Jaroslav;
    • Vostry, Martin;
    • Kostecka, Arnost;
    • Hajkova, Hana;
    • Neuwirtova, Radana;
    • Siskova, Magda;
    • Sponerova, Dana;
    • Cermak, Jaroslav;
    • Mikulenkova, Dana;
    • Cervinek, Libor;
    • Brezinova, Jana;
    • Michalova, Kyra;
    • Fuchs, Ota
    Publication type:
    Article
    47

    Outcomes in RBC transfusion-dependent patients with Low-/ Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.

    Published in:
    European Journal of Haematology, 2014, v. 93, n. 5, p. 429, doi. 10.1111/ejh.12380
    By:
    • Giagounidis, Aristoteles;
    • Mufti, Ghulam J.;
    • Mittelman, Moshe;
    • Sanz, Guillermo;
    • Platzbecker, Uwe;
    • Muus, Petra;
    • Selleslag, Dominik;
    • Beyne‐Rauzy, Odile;
    • Boekhorst, Peter;
    • Cañizo, Consuelo;
    • Guerci‐Bresler, Agnès;
    • Nilsson, Lars;
    • Lübbert, Michael;
    • Quesnel, Bruno;
    • Ganser, Arnold;
    • Bowen, David;
    • Schlegelberger, Brigitte;
    • Göhring, Gudrun;
    • Fu, Tommy;
    • Benettaib, Bouchra
    Publication type:
    Article
    48
    49
    50